BACKGROUND: Although Roux-en-Y gastric bypass (RYGBP) is one of the preferred bariatric procedures in obese individuals, the efficacy of this procedure in the setting of super-obesity [body mass index (BMI) >/=50] is unclear. The aim of this study was to compare the efficacy of laparoscopic (L) RYGBP to reverse metabolic syndrome, inflammation, and insulin resistance in super-obese women compared to morbidly obese women. METHODS: Seventy-three consecutive women were enrolled in this prospective study. Anthropometric, metabolic, and inflammatory biological parameters were assessed in 18 super-obese and 55 morbidly obese women before LRYGBP and 1 year after surgery. Metabolic syndrome was diagnosed according to the International Diabetes Federation definition. RESULTS: Before surgery, super-obese women had a higher BMI, fat mass, blood insulin, and HOMA1-IR than morbidly obese women. Both groups had similar serum levels of C-reactive protein and orosomucoid. The incidence of metabolic syndrome, type 2 diabetes, and increased liver enzymes was comparable in the two groups. One year after LRYGBP, metabolic syndrome, type 2 diabetes, metabolic and inflammatory biological parameters were improved in the whole study population. A similar degree of improvement was observed in super-obese and morbidly obese women, although BMI and fat mass were persistently higher in super-obese patients. CONCLUSIONS: One year after surgery, LRYGBP was equally effective at reversing metabolic syndrome, inflammation, and insulin resistance in morbidly obese and super-obese women.
BACKGROUND: Although Roux-en-Y gastric bypass (RYGBP) is one of the preferred bariatric procedures in obese individuals, the efficacy of this procedure in the setting of super-obesity [body mass index (BMI) >/=50] is unclear. The aim of this study was to compare the efficacy of laparoscopic (L) RYGBP to reverse metabolic syndrome, inflammation, and insulin resistance in super-obesewomen compared to morbidly obesewomen. METHODS: Seventy-three consecutive women were enrolled in this prospective study. Anthropometric, metabolic, and inflammatory biological parameters were assessed in 18 super-obese and 55 morbidly obesewomen before LRYGBP and 1 year after surgery. Metabolic syndrome was diagnosed according to the International Diabetes Federation definition. RESULTS: Before surgery, super-obesewomen had a higher BMI, fat mass, blood insulin, and HOMA1-IR than morbidly obesewomen. Both groups had similar serum levels of C-reactive protein and orosomucoid. The incidence of metabolic syndrome, type 2 diabetes, and increased liver enzymes was comparable in the two groups. One year after LRYGBP, metabolic syndrome, type 2 diabetes, metabolic and inflammatory biological parameters were improved in the whole study population. A similar degree of improvement was observed in super-obese and morbidly obesewomen, although BMI and fat mass were persistently higher in super-obesepatients. CONCLUSIONS: One year after surgery, LRYGBP was equally effective at reversing metabolic syndrome, inflammation, and insulin resistance in morbidly obese and super-obesewomen.
Authors: Maria de Fátima Haueisen Sander Diniz; Valéria Maria de Azeredo Passos; Marco Túlio Costa Diniz Journal: Curr Opin Clin Nutr Metab Care Date: 2006-09 Impact factor: 4.294
Authors: Derek K Hagman; Ilona Larson; Jessica N Kuzma; Gail Cromer; Karen Makar; Katya B Rubinow; Karen E Foster-Schubert; Brian van Yserloo; Peter S Billing; Robert W Landerholm; Matthew Crouthamel; David R Flum; David E Cummings; Mario Kratz Journal: Metabolism Date: 2017-02-02 Impact factor: 8.694
Authors: Anne Sophie Schneck; Rodolphe Anty; Albert Tran; Audrey Hastier; Imed Ben Amor; Jean Gugenheim; Antonio Iannelli; Thierry Piche Journal: Obes Surg Date: 2016-07 Impact factor: 4.129
Authors: Jose Antonio Gracia-Solanas; M Elia; V Aguilella; J M Ramirez; J Martínez; M A Bielsa; M Martínez Journal: Obes Surg Date: 2011-02 Impact factor: 4.129
Authors: Ammon Handisurya; Michaela Riedl; Greisa Vila; Christina Maier; Martin Clodi; Thomas Prikoszovich; Bernhard Ludvik; Gerhard Prager; Anton Luger; Alexandra Kautzky-Willer Journal: Obes Surg Date: 2009-06-09 Impact factor: 4.129
Authors: Mario Kratz; Derek K Hagman; Jessica N Kuzma; Karen E Foster-Schubert; Chun P Chan; Skye Stewart; Brian van Yserloo; Emily O Westbrook; David E Arterburn; David R Flum; David E Cummings Journal: Obesity (Silver Spring) Date: 2016-05-26 Impact factor: 5.002
Authors: Erica S Rinella; Christopher Still; Yongzhao Shao; G Craig Wood; Xin Chu; Brenda Salerno; Glenn S Gerhard; Harry Ostrer Journal: J Clin Endocrinol Metab Date: 2013-04-30 Impact factor: 5.958